TRDMT1

Across TCGA pan-cancer cohorts, TRDMT1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TRDMT1 data layer compared with 28 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TRDMT1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRDMT1 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

HNSC, LSCC, and GBM are the cancer types where TRDMT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.355	1.000	.006	19	view →
LSCC	DFS	Median	III,IV	1.000	0.572	.002	14	view →
GBM	DFS	Tertile	All	0.157	0.704	.010	5	view →
LUAD	DFS	Median	III,IV	0.409	0.922	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TRDMT1–HNSC (DFS)

Open the HNSC breakdown →